The selected models harbored molecular alterations commonly described in the matched tumor types, such as loss of PTEN expression present in around 30% in patients with TNBC [35] and LADC [36] or KRAS mutation described in around one third of LADC [37] and LGSOC [38]. Here, KRAS is linked to neoplasm.